Filter by

  • REACH Clinical Trial

    Diagnosis Requirements: Mild cognitive impairment or Alzheimer’s
    Age Eligibility: Ages 55 to 89 years

    The REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates. The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.

  • ART-AD Study

    Diagnosis Requirements: Alzheimer's disease
    Age Eligibility: Ages 50 to 80 years

    A new approach to dementia treatment- targeting the proteins connected to memory loss. Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B. Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.

  • AHEAD 3-45 Study

    Diagnosis Requirements: None
    Age Eligibility: Ages 55 to 80 years

    This study reviews a new treatment to prevent memory decline and slow the earliest symptoms of Alzheimer’s disease.

  • CARPE DIEM Study: Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway

    Diagnosis Requirements: Mild Cognitive Impairment or Early Stages of Alzheimer’s Disease
    Age Eligibility: Ages 55 to 85 years

    The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

  • SIESTA Study: Sleep Issues – Efficacy and Sensitivity of Technological Assessments

    Diagnosis Requirements: Parkinson's Disease
    Age Eligibility:

    To provide easier, convenient testing in the future, this study will evaluate if at-home devices, like the FitBit, can detect these sleep disturbances in Parkinson’s with similar accuracy as a clinic-based sleep study.

  • Heart Function and Brain Health Study

    Diagnosis Requirements: Normal Heart Function or Diastolic Dysfunction
    Age Eligibility: Ages 60 years or older

    The purpose of this clinical trial is to study heart function in relation to brain health.

  • SToMP-AD Study: Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease

    Diagnosis Requirements: Alzheimer's Disease
    Age Eligibility: Ages 65 years or older

    The purpose of this study is to evaluate if a combination of two medications may be an effective intervention for treating AD symptoms in future studies.

  • PEACE-AD Trial

    Diagnosis Requirements: Alzheimer's disease
    Age Eligibility:

    The trial will evaluate Prazosin, an FDA-approved drug, as treatment for people with severe agitation/disruptive behavior in Alzheimer’s disease.

  • 7T MRI Study of How COVID-19 Affects the Brain

    Diagnosis Requirements: None
    Age Eligibility: Ages 45 to 80 years recovered from COVID-19 in the last 6 to 15 months or developed an illness other than COVID-19 in the past 6 to15 months or have not had any illnesses requiring hospitalization in the last 2 years.

    Studying COVID-19’s long-term neurological and psychological impacts.

  • Diverse Vascular Contributions to Cognitive Impairment and Dementia (VCID)

    Diagnosis Requirements:
    Age Eligibility: Between the ages of 65 and 90 and you notice a decline in your memory or thinking over the last 1-3 years

    The results of this study will be used to develop and validate a predictive risk model to inform future care.